Arcutis Biotherapeutics: Matsuda Masaru sells 1,800 shares at $13.78 per share.

Arcutis Biotherapeutics, Inc. (ARQT) has announced that Matsuda Masaru, a member of the company's board of directors, has sold 1,800 shares of the company's stock at a price of $13.78 per share on May 28, 2023.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has announced that Masaru Matsuda, a board member, sold 1,800 shares of the company's stock on May 28, 2023, at a price of $13.78 per share. This transaction, disclosed in a filing with the Securities & Exchange Commission, indicates a decrease in Matsuda's ownership in the company [1].

The sale of 1,800 shares by Matsuda represents a 0.08% reduction in his total ownership, as he now holds 204,399 shares valued at approximately $3,106,864.80. This transaction follows a previous sale of 5,030 shares on May 2, 2023, at an average price of $15.20 per share [1].

Arcutis Biotherapeutics, Inc. focuses on developing and commercializing treatments for dermatological diseases, with its lead product candidate, ARQ-151, a topical roflumilast cream, completing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis [1].

In recent quarters, the company has seen significant institutional investment. BNP Paribas Financial Markets bought 79,815 shares in the 4th quarter of 2022, valued at approximately $1,112,000. Additionally, several hedge funds have added to their stakes in the company [1].

Analysts have shown varying opinions on the stock. Mizuho raised their target price from $20.00 to $21.00 and gave the stock an "outperform" rating. Needham & Company, Jefferies Financial Group, HC Wainwright, and Goldman Sachs have also issued "buy" ratings with target prices ranging from $16.00 to $21.00. The stock currently has an average rating of "Moderate Buy" and an average target price of $18.80 [1].

Arcutis Biotherapeutics reported ($0.20) earnings per share for the quarter ending May 6, 2023, beating analysts' consensus estimates of ($0.21). The company's revenue for the quarter was $65.85 million, compared to analysts' expectations of $64.80 million [1].

The stock's price performance has been volatile, with a 52-week low of $6.99 and a 52-week high of $17.75. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -7.81, and a beta of 1.87 [1].

References:
[1] https://www.marketbeat.com/instant-alerts/filing-79815-shares-in-arcutis-biotherapeutics-inc-nasdaqarqt-acquired-by-bnp-paribas-financial-markets-2025-05-21/